Federal Advisory Panel Rejects Warning for ADHD Drugs
An FDA advisory panel rejected calls to add warnings regarding the cardiovascular and psychiatric risks of attention deficit hyperactivity disorder drugs to their labels. Although the FDA does not have to follow the panel's decision, it usually does. In February, a different FDA advisory panel strongly recommended the addition of such a warning to ADHD drug labels.